Breast cancer drug Enhertu costs about £8,000 per session and is only available privately in England, but is offered on the ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the European Commission has approved the expanded use of Enhertu ...

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...

WHEN Sue Ware was planning her mum’s funeral after losing her to breast cancer, she never dreamed she would also get the disease.  But that’s exactly what happened. Just five days after her ...

ENHERTU (5.4 mg/kg) is approved in more than 75 countries worldwide for the treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer who have ...

Daiichi Sankyo Company, Limited leads in ADC tech with Enhertu, strong partnerships, revenue growth, and global market leadership. Click to know more on why DSNKY is a Buy.

Enhertu's approval extends to 75 nations, inclusive of the EU, for individuals with HER2 low metastatic breast cancer who have previously received systemic therapy or experienced disease ...

(AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu (trastuzumab deruxtecan) has been approved in the European Union as a treatment for adults with advanced breast cancer. It is for patients with ...

This approval enables the use of Enhertu as a monotherapy for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have ...

Daiichi Sankyo (DSNKY) and AstraZeneca’s Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hor ...

This approval enables the use of Enhertu as a monotherapy for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have previously ...